Curaleaf Holdings, Inc. filed a Form 8-K on November 5, 2026, disclosing that on November 3, 2026, the company issued a statement regarding an alternative proposal for Aurora Cannabis, with the press release attached as Exhibit 99.1.

Key Highlights

  • Event date: Curaleaf issued its statement regarding the alternative proposal for Aurora Cannabis on November 3, 2026.
  • Filing type: The report was filed under Item 8.01 (Other Events) and also checked as a written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  • No securities registered under Section 12(b): According to the filing, Curaleaf has no securities registered pursuant to Section 12(b) of the Act.
  • Signing officer: The report was signed by Peter Clateman, Chief Legal Officer of Curaleaf Holdings, Inc.
  • Exhibit included: A press release dated November 3, 2026, was attached as Exhibit 99.1 to the filing.
  • Not "filed" for Section 18 purposes: The filing states the information, including Exhibit 99.1, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Curaleaf's November 3, 2026 Statement on the Aurora Cannabis Proposal

According to the Form 8-K filed with the U.S. Securities and Exchange Commission, Curaleaf Holdings, Inc., a cannabis company incorporated in British Columbia, Canada, with principal executive offices at 250 Harbor Drive, Third Floor, Stamford, Connecticut 06902, disclosed that it issued a public statement on November 3, 2026, addressing an alternative proposal relating to Aurora Cannabis. The specific content of that statement is contained in the press release attached as Exhibit 99.1 to the filing, which is not reproduced in the body of the 8-K itself.

The filing was checked as a written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425), indicating the disclosure is connected to a potential transaction subject to that rule. The registrant noted that the filing carries Commission File Number 333-249081 and IRS Employer Identification Number 98-1461045. The filing explicitly states that the information furnished, including the press release, is not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934, and will not be incorporated by reference into other registration statements unless expressly specified.

The report was authorized and signed by Peter Clateman in his capacity as Chief Legal Officer of Curaleaf Holdings, Inc. on November 3, 2026. The filing also notes that Curaleaf is not an emerging growth company as defined under applicable SEC rules. No securities of the registrant are registered pursuant to Section 12(b) of the Act, according to the filing's cover page.

What Was Disclosed

Curaleaf Holdings, Inc. disclosed via an Item 8.01 Form 8-K that it issued a statement on November 3, 2026, regarding an alternative proposal for Aurora Cannabis. The press release containing that statement was attached as Exhibit 99.1 to the filing.